These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

755 related items for PubMed ID: 22011753

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Local estrogen therapy--clinical implications--2012 update].
    Kokot-Kierepa M, Bartuzi A, Kulik-Rechberger B, Rechberger T.
    Ginekol Pol; 2012 Oct; 83(10):772-7. PubMed ID: 23383564
    [Abstract] [Full Text] [Related]

  • 3. Identifying and treating sexual dysfunction in postmenopausal women: the role of estrogen.
    Simon JA.
    J Womens Health (Larchmt); 2011 Oct; 20(10):1453-65. PubMed ID: 21819250
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
    Bachmann GA, Komi JO, Ospemifene Study Group.
    Menopause; 2010 Oct; 17(3):480-6. PubMed ID: 20032798
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.
    Al-Baghdadi O, Ewies AA.
    Climacteric; 2009 Apr; 12(2):91-105. PubMed ID: 19117185
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.
    North American Menopause Society.
    Menopause; 2007 Apr; 14(3 Pt 1):355-69; quiz 370-1. PubMed ID: 17438512
    [Abstract] [Full Text] [Related]

  • 12. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
    McLendon AN, Clinard VB, Woodis CB.
    Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
    [Abstract] [Full Text] [Related]

  • 13. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women.
    Levine KB, Williams RE, Hartmann KE.
    Menopause; 2008 Oct; 15(4 Pt 1):661-6. PubMed ID: 18698279
    [Abstract] [Full Text] [Related]

  • 14. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
    Pinkerton JV, Stanczyk FZ.
    Menopause; 2014 Mar; 21(3):309-19. PubMed ID: 23777900
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Vulvovaginal atrophy: new and upcoming approaches.
    Simon JA.
    Menopause; 2009 Mar; 16(1):5-7. PubMed ID: 19131842
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
    Bachmann G, Bobula J, Mirkin S.
    Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.